. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Anesth Analg. 2020 Dec;131(6):1911–1922. doi: 10.1213/ANE.0000000000005223

Table 4:

Outcome measures.

Outcome	Baseline (n=7212)	Intervention (n=4416)	QI (n=8311)	Chi² p^*	aOR per month^a	p
Beers list medication^b (primary outcome)	2397 (33%)^*	1200 (27%)	1937 (23%)^*	<0.001	0.97 [0.95–0.998]	0.033
Delirium^c (secondary outcome)	365/4884 (7.5%)	280/3051 (9.2%)	477/5606 (8.5%)	0.020	0.98 [0.91–1.05]	0.52
Preferred antiemetic^d (exploratory analysis)	2634 (36%)	1673 (38%)	3214 (39%)	0.022	1.01 [0.99–1.04]	0.38
Beers list antiemetic^e (exploratory analysis)	268 (3.7%)^*	127 (2.9%)	165 (2.0%)^*	<0.001	0.96 [0.91–1.02]	0.21
Midazolam (exploratory analysis)	2073 (29%)	1042 (24%)	1677 (20%)	<0.001	0.97 [0.94–0.997]	0.031

Abbreviations: QI, quality improvement. aOR, adjusted odds ratio.

^a.

Adjusted odds ratio comparing the change in slopes between baseline and the QI period calculated via segmented regression adjusting for patient demographics and comorbidities.

^b.

Composite of any use of diphenhydramine, lorazepam, meperidine, midazolam, prochlorperazine, promethazine, or scopolamine.

^c.

Delirium incidence was calculated only in patients who were hospitalized at least 1 night; the denominator is reported in the table.

^d.

Composite of any use of dexamethasone, haloperidol, or metoclopramide.

^e.

Composite of any use of prochlorperazine, promethazine, or scopolamine.

Potentially contributing to the overall statistically significant chi squared test based on post-hoc examination of the residuals.